Nasdaq

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once ...

NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...

Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions

Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced that management will participate in the ...
Nasdaq

Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple ...

NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Business Insider

Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for ...

NESS ZIONA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today ...
MarketWatch

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting ...

The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...